Semax and PGP boost neuroglial proliferation; only Semax reduces ischemic brain damage in rats
Background
Cerebral ischemia causes rapid, devastating damage to nervous tissue, and current clinical options remain limited in their ability to promote repair or halt neuronal loss. The neuropeptide preparation Semax (Met-Glu-His-Phe-Pro-Gly-Pro) has already entered clinical practice for treatment of severe brain blood circulation disorders, yet the full spectrum of its tissue-level effects is poorly understood. Its C-terminal tripeptide PGP is structurally derived from Semax, and whether PGP shares, overlaps, or diverges from Semax's therapeutic actions at the cellular and histological level had not been directly compared. Clarifying these relationships is essential for understanding which fragment of the peptide drives which biological effect.
Study Design
A pilot study exposed normal rats and rats subjected to a model of incomplete global brain ischemia to Semax (Met-Glu-His-Phe-Pro-Gly-Pro) and its C-terminal tripeptide PGP. Both peptides were evaluated in control (non-ischemic) animals and in the ischemic model. Primary endpoints were functional morphology of nervous tissue cells, capillary network activation, and proliferative activity of neuroglia, blood vessel endothelium, and progenitor cells in the subventricular zone. Histological analysis was the primary assay method, making this the first histological-level characterisation of proliferative effects for these compounds.
Results
In control animals, both Semax and PGP activated the capillary network and produced similar morphological changes in neurons and neuropil regions. Both peptides increased proliferation of neuroglia, blood vessel endothelium, and progenitor cells in the subventricular zone — a finding reported here for the first time at the histological level.
Only Semax — not PGP — abated the manifestation of ischemic damage to nervous tissue under experimental ischemia conditions.
The protective effect of Semax in the ischemic setting was attributed to two distinct mechanisms: a decrease in vascular stasis symptoms and a trophic effect of the peptide on nervous tissue. PGP did not replicate this neuroprotective profile despite sharing the proliferative actions seen in normal brain, indicating a functional divergence between the full Semax sequence and its C-end fragment specifically under ischemic stress.
Key Findings
- Both Semax and PGP activated the capillary network and altered neuron/neuropil morphology in normal rat brain.
- First histological demonstration that Semax and PGP increase neuroglial and endothelial proliferation.
- Both peptides enhanced progenitor cell proliferation in the subventricular zone.
- Only Semax, not PGP, reduced ischemic nervous tissue damage in the incomplete global ischemia model.
- Semax's neuroprotection was linked to reduced vascular stasis and a trophic effect on nervous tissue.
Why It Matters
Semax's superiority over PGP under ischemia suggests the N-terminal portion of the molecule — beyond the shared PGP tripeptide — contributes critical neuroprotective properties that cannot be reduced to its C-end fragment alone. For clinicians and researchers, this supports continued development of the full Semax sequence rather than shorter analogues for ischemic indications. Both peptides' shared ability to drive neuroglial and endothelial proliferation in normal brain opens a separate question about their utility in non-ischemic neuroregeneration or recovery contexts. The pilot nature of this work and the animal model mean that translation to human dosing protocols requires considerably more mechanistic and pharmacokinetic data before any clinical or self-administration protocol can be responsibly designed.
TitrateLab articles covering Semax
Written by TitrateLab, separately from the study summarized above.
